Treatment options for multiple myeloma patients with high-risk disease
- 116 Downloads
Multiple myeloma is a heterogeneous malignant disorder with a variable clinical course suggestive of diverse biological factors that have important prognostic implications. Despite development of several new therapeutic agents and substantially effective novel combination regimens, myeloma remains an incurable disease. There is an emphasis to define new biologic parameters to accurately identify patients with aggressive disease biology. This will allow more informed treatment decisions based on the biology of the disease, resulting in further optimization of management strategies in specific patient subgroups. Among biological parameters of risk stratification, cytogenetics has emerged as arguably the most important dependable and clinically convenient. These are being increasingly utilized to develop therapeutic stratification in newer clinical trials. Appraisal of current data suggests that patients with high-risk cytogenetics have a worse prognosis. However, treatment with novel agents has changed this variable. There is emerging evidence that patients with aggressive disease biology are fairing better with innovative treatment regimens utilizing a combination of conventional and novel agents. This review focuses on current and emerging data about defining high-risk disease in multiple myeloma and the various therapeutic options for this group of patients.
KeywordsMultiple myeloma Cytogenetics High-risk FISH
Conflict of interest statements
Sikander Ailawadhi: Speaker’s Bureau—Celgene, Millennium, Ortho BioTech; Advisory board—Millennium; Aisha Masood: No disclosures to report; Taimur Sher: Advisory board for Millennium; Kena C. Miller: Speakers bureau for Celgene, Millennium, Cephalon, Medtonic/Kyphon; Advisory Board for Celgene and Millennium; Margaret Wood: No disclosures to report; Kelvin Lee: No disclosures to report; Asher Chanan-Khan: Speakers bureau—Celgene, Millennium; Advisory board—Celgene, Millennium. All authors received an honorarium for their participation in this supplement.
- 14.Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the pethema/gem cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737–44.CrossRefPubMedGoogle Scholar
- 23.Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy i: interpretation in the context of global gene expression. Blood. 2003;101:3849–56.CrossRefPubMedGoogle Scholar
- 25.Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy ii. Br J Haematol. 2003;120:44–52.CrossRefPubMedGoogle Scholar
- 29.Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol. 2007;136:615–23.CrossRefPubMedGoogle Scholar
- 37.Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008;111:968–9.CrossRefPubMedGoogle Scholar
- 38.Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myelome. J Clin Oncol. 2008;26:4798–805.CrossRefPubMedGoogle Scholar
- 47.Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (rad) in patients with relapsed and refractory multiple myeloma: a report from the german myeloma study group dsmm (deutsche studiengruppe multiples myelom). Blood. 2009;113:4137–43.CrossRefPubMedGoogle Scholar
- 52.Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.PubMedGoogle Scholar
- 53.Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (ifm99–03 trial) with tandem autologous stem cell transplantation (ifm99–04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–80.CrossRefPubMedGoogle Scholar